CYDY fiddling at apex of corrective wedge - Now or New Year?The previous pop back to old purple bottoms line predicted here in September fizzled a bit at the top peaking early around $2.55 instead of the expected $2.75-3.00. Now we're filling in leg E of the giant corrective wedge since July 2020 $10 high. While the shareholder vote this morning did not me
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0173 USD
−49.84 M USD
0.00 USD
1.22 B
About CytoDyn Inc.
Sector
Industry
CEO
Jacob P. Lalezari
Website
Headquarters
Vancouver
Founded
2002
FIGI
BBG000BYS4X7
CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its pipeline includes Leronlimab Clinical Development Pipeline and Long-Acting CCR5 Inhibitor Development Pipeline. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
CYDY 2MTEST
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company was founded by Allen D. Allen
CYDY 1W TEST
It's not your textbook hns
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company wa
Cytodyn due for a pop into OctoberCYDY performance has been dismal since the out-of-protocol "hold your horses!" FDA letter in late May, continuing down in a withering C wave. A great article posted by our friends KenChowder and ohm on Democrat blog dailykos.com yesterday was angrily removed by complainers conditioned to treat any
Cytodyn still stuck in corrective triangle from July $10 spikeThe FDA explanatory letter this week dropped Cytodyn to $1.77 Wednesday, lower than March $2 low but higher than November $1.63 low. We have a nice clean 5-wave impulse up off the lows back to $2.19 to end the week. It's tiny so far but at least a sign that Wednesday was washout low. So I'm stick
CYDY Finishing the big consolidation triangle?CYDY has rallied strongly from the $2 floor the past week, doubling to $4.2 this morning on recent understanding that results of CD12 study were hampered by the FDA's 2-dose limitation. With 4-doses spread over the 4-week patient evaluations, more severe patients would likely have been saved.
If w
CYDY update: still looks promising to me.There was a disappointing drop in price after my first posting. (see link below). Since then there has been very encouraging news on one of its drugs. The good news: Although in small trials, the drug appears to be very helpful in assisting treatment in severe infections with Covid-19. Bad news: mul
CYDY fizzled rally leaves long triangle consolidationThough CYDY managed to rally over the winter from 1.85 to 7.4 on COVID trial results speculation, the 1,2,i,ii,iii nesting sequence we spotted in December never materialized into the expected sequence of higher highs iv,v,4,5 into $8 and $9. The rally stretched and distorted in time ending as a 5-w
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of CYDY is 0.2049 USD — it has increased by 1.19% in the past 24 hours. Watch CytoDyn Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange CytoDyn Inc. stocks are traded under the ticker CYDY.
CYDY stock has risen by 1.19% compared to the previous week, the month change is a 3.66% rise, over the last year CytoDyn Inc. has showed a 29.68% increase.
CYDY reached its all-time high on Jun 30, 2020 with the price of 10.0100 USD, and its all-time low was 0.0552 USD and was reached on Feb 11, 2019. View more price dynamics on CYDY chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CYDY stock is 8.75% volatile and has beta coefficient of 0.51. Track CytoDyn Inc. stock price on the chart and check out the list of the most volatile stocks — is CytoDyn Inc. there?
Today CytoDyn Inc. has the market capitalization of 251.56 M, it has decreased by −15.79% over the last week.
Yes, you can track CytoDyn Inc. financials in yearly and quarterly reports right on TradingView.
CytoDyn Inc. is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
CYDY net income for the last quarter is −4.77 M USD, while the quarter before that showed 19.23 M USD of net income which accounts for −124.80% change. Track more CytoDyn Inc. financial stats to get the full picture.
No, CYDY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 9 employees. See our rating of the largest employees — is CytoDyn Inc. on this list?
Like other stocks, CYDY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CytoDyn Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CytoDyn Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CytoDyn Inc. stock shows the sell signal. See more of CytoDyn Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.